HSK39004

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Safety and EfficacyChronic Obstructive Pulmonary DiseaseTics

131 competitors in Safety and Efficacy

#DrugCompanyPhaseTrials

1

Avastin

Roche

Phase 3

32

Actemra

Roche

Phase 3

13

Humira

RRanbaxy Laboratories Limited

Phase 3

34

Rayos

RRoxane Laboratories

Phase 3

35

Empaveli

Apellis Pharmaceuticals

Phase 3

26

CAB LA

GSK

Phase 3

17

B/F/TAF

Gilead

Phase 3

58

Eloxatin

Teva

Phase 2

29

Nuzyra

PParatek Pharmaceuticals Inc

Phase 3

110

Bomedemstat

Merck & Co.

Phase 3

1Show 37 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease2 trials

Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)

Active, not recruiting·Haisco Pharmaceutical Group Co., Ltd.·Phase 2·NCT07140328·50 enrolled

Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)

Not yet recruiting·Haisco Pharmaceutical Group Co., Ltd.·Phase 2·NCT07108699·180 enrolled

Clinical Trial2 trials

Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Primary Efficacy of HSK39004 Suspension for Inhalation

Completed·Haisco Pharmaceutical Group Co., Ltd.·Phase 1·NCT06905847·63 enrolled

Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HSK39004 Dry Powder Inhalation

Completed·Haisco Pharmaceutical Group Co., Ltd.·Phase 1·NCT06971198·26 enrolled

Tics1 trial

A Clinical Study Evaluating the Pharmacokinetics and Pharmacodynamics of HSK39004 Inhalation Suspension in COPD Patients

Active, not recruiting·Haisco Pharmaceutical Group Co., Ltd.·Phase 2·NCT07331402·12 enrolled

Safety and Efficacy1 trial

Long-Term Safety and Efficacy of HSK39004 Dry Powder Inhaler in COPD

Not yet recruiting·Haisco Pharmaceutical Group Co., Ltd.·Phase 2·NCT07425210·300 enrolled

Details

Drug Info

Related News